Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
IRVINE, Calif., Aug. 24, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Avinger shares on or about the IPO, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Avinger filed documents in connection with the IPO that contained materially false and misleading statements and/or failed to disclose: that Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; that Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result, the Company was experiencing lower sales and revenues. When this information was released, Avinger’s share price dropped, causing investors harm according to the Complaint. On May 3, 2017, the stock closed at $0.57 per share, a decline of over 95% from the IPO price.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
